University of Melbourne-led research has shown the flavonoid pinocembrin, derived from Australian eucalyptus trees, has strong anti-inflammatory properties.

Neurotech International (ASX:NTI) says preclinical studies demonstrate that NTI164 can improve the efficacy of prednisone at low doses.

Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced an agreement with a US university for a new cell platform technology.

AusBiotech is calling for thought leadership articles on innovative approaches, contributions or analyses to include in the April 2022 edition of the Australasian Biotechnology journal.

New research from St Vincent’s Institute of Medical Research on lipoedema could support the development of new treatments and the development of a diagnostic screening test.

Bionomics (ASX:BNO) has announced that the US FDA has granted Fast Track designation to the BNC210 development program for the acute treatment of Social Anxiety Disorder and other anxiety-related disorders.

Zelira Therapeutics (ASX:ZLD) has announced ethics approval has been granted for the Phase 2a clinical trial of its cannabinoid formulation, ZTL-106, in treating patients with chronic pain.

BARD1 said it has signed an agreement with Griffith University to provide consultancy and scientific services to support the development and evaluation of an exosome-based RNA test for the detection of ovarian and breast cancers.

The Victorian government says researchers in the state have produced Australia's first mRNA COVID-19 vaccine candidate.

AusBiotech has welcomed The New Frontier - Delivering better health for all Australians - the final report delivered by the Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia.

Emyria (ASX:EMD) has announced the appointment of experienced drug development executive Dr Karen Smith to its board.

Digital health company ResApp (ASX:RAP) has announced TGA clearance and CE Mark certification for its standalone cough counter smartphone application.

Q-Sera has announced a partnership with Japanese medical device company Terumo that will see its RAPClot rapid serum tube technology manufactured and used in Japan.

BioCina acquired the facility from Pfizer and it has now been launched as a biologics contract development and manufacturing facility.

Nominations have opened for the Prime Minister’s Prizes for Science, Australia’s most prestigious awards for outstanding achievements in scientific research and research-based innovation.

Research led by the Centenary Institute and the University of Technology Sydney has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment for chronic obstructive pulmonary disease.

Biotron (ASX:BIT) has announced that its lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute in the US.